|The following article features coverage from the ASCO Genitourinary Cancers Symposium 2022. Click here to read more of Cancer Therapy Advisor’s conference coverage.|
Investigators who studied a population of patients with metastatic clear cell renal cell carcinoma (mRCC) found that Black men younger than 50 years had worse overall survival compared with other age groups, Black women, and White patients, according to a presentation at the ASCO Genitourinary Cancers Symposium 2022.
“Most of the literature to date has focused on disparities impacting Black patients with localized RCC,” said lead investigator Claud M. Grigg Jr., MD, of Levine Cancer Institute in Charlotte, North Carolina. “But we have very little understanding of which factors impact outcome in the metastatic setting. Oncologists and urologists should be aware that young Black men have poor outcomes with this disease, but should still provide the same care as for any other patient.”
The study by Dr Grigg and colleagues included 900 Black men, 461 Black women, 13,422 White men, and 6363 White women. On multivariate analysis, Black race was significantly associated with a 14% increased risk for death compared with the overall cohort, the investigators reported.
When stratified by age and race, the investigators observed that men had similar or superior survival compared with women in most subgroups. Black men younger than 50 years, however, had significantly lower median overall survival compared with Black women, White women, and White men in the same age group (10.4 vs 17.1, 23.2, and 22.1 months, respectively).
“Potential hypotheses to explain this disparity include differences in obesity and smoking incidence in this population as well as unmeasured factors impacting access to care,” the authors concluded in their study abstract.
Dr Grigg’s team noted that Black patients were less likely to have private insurance, lung metastases, or to live in high income zip codes. They also were more likely to have liver metastases.
Disclosures: Some study authors declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.
Read more of Cancer Therapy Advisor’s coverage of ASCO GU 2022 by visiting the conference page.
Grigg C, Trufan SJJ, Riggs SB, et al. Survival of young black males with metastatic clear cell renal cell carcinoma. Presented at ASCO GU 2022; February 17-19, 2022. Abstract 294.
This article originally appeared on Renal and Urology News